EyePoint Pharmaceuticals, Inc. — Director's Dealing 2023

Dec 6, 2023

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2023-12-04

Reporting Person: Cormorant Asset Management, LP (N/A)
Reporting Person: Cormorant Global Healthcare Master Fund, LP (N/A)
Reporting Person: Chen Bihua (N/A)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	3530943	Indirect

Footnotes

F1: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 3 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

F2: Represents 3,530,943 shares beneficially owned by the Master Fund.